Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment.

NCT02894554 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT02894554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02894554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment.
Lead sponsor
National Taiwan University Hospital
Phase
Phase 4
Overall status
Terminated
Start date
July 31, 2014
Completion date
July 31, 2015
Enrollment
19 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hbsag-positive renal allograft recipients